EUCTR2007-000229-23-IT进行中（未招募）不适用
Renal safety evaluation after dotarem-enhanced MRI compared with non-enhanced MRI in patients at high risk of developing contrast medium induced nephropathy - RESCUE
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- GUERBET
- 入组人数
- 134
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female, aged ≥ 18 years; Female of childbearing potential must have effective contraception (contraceptive pill or Intra-Uterine Device), or be surgically sterilized, or post-menopausal (minimum 12 months of amenorrhea) or must have a documented negative urine or blood pregnancy test at screening; Patient presenting with a known stable stage III to stage IV renal insufficiency according to the K/DOQI definition, i.e., 15 < estimated GFR < 60 ml/min/1.73m? according to MDRD formula; stability will be demonstrated with 2 consecutive values (within 15% of each other): a previous value obtained at least one week in advance (not more than 6 months in advance) and the most recent one obtained prior to the study procedure, on the same day or on the day before; Patient scheduled to undergo a contrast enhanced MRI or unenhanced MRI examination to specify a diagnosis; Patient receiving angiotensin-converting enzyme inhibitors, angiotensine II receptor blockers ( sartans ), diuretics and fibrates, must be receiving these drug(s) at stable dosage(s) for at least 2 weeks; in addition the dosage(s) should not be modified for the whole study duration (i.e., until 72 hours ? 24hrs or 14 days after the imaging procedure); Patient able to understand and having provided written informed consent to participate in the trial; Patient for whom blood samples can be obtained on the day of the imaging procedure or on the day before and 72 hours (? 24 hrs) after the examination; Patient with National health insurance.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patient with a contraindication to MRI (e.g., pacemaker, aneurysm clip, severe claustrophobia, metallic joint replacement or others according to the imaging laboratory`s standard practice); Patient who has a diagnosis of a hemodynamic instability (cardiogenic shock persistent systolic pressure < 90 requiring inotropic support) or acute myocardial infraction within 15 days prior the inclusion; Patient who needs haemodialysis; Patient with known allergy to gadolinium chelates (only applicable for patient undergoing Dotarem-enhanced MRI); Patient receiving anticalcineurine drugs, such as ciclosporine, unless the patient has been having a stable (variation ≤ 15%) creatinine level for at least 6 months, as demonstrated with available creatinine values, and has been receiving the drug at stable dosage for at least 6 months; this dosage should not be modified for the whole study duration (i.e., until 72 hours ? 24hrs or 14 days after the imaging procedure); Patient receiving any other medication known to be nephrotoxic or to cause increases in serum creatinine level (e.g., selective inhibitors of cyclo-oxygenase 2, anti-vascular Endothelium Growth Factors, vancomycine, aciclovir, aminoglycosides, amphotericin B, polymixin, platinium complexes, non-steroidal anti-inflammatory treatment except acetyl salicylic acid, etc.) within 2 weeks before first blood sample and for the whole study duration (i.e., until 72 hours ? 24hrs or 14 days after the imaging procedure); Patients planned to either undergo surgery or receive chemotherapy within 72 hours post-procedure (i.e., before the 72 hours post-procedure blood test); Patient having had an imaging procedure (MRI or CT imaging, with contrast medium or not) within 7 days of entering this protocol; Patient with a planned imaging procedure (MRI or CT imaging, with contrast medium or not) within 72 hours post-procedure; Patient having participated in any investigational drug study within 30 days prior the study enrolment or planned to participate within 72 hours post-procedure; Any condition which, based on the investigator`s clinical judgement, would prevent the patient from completing all trial assessments and visits; Patient under guardianship and/or inability or unwillingness to cooperate with the requirements of this trial; Patient with newly discovered unstable diabetes (i.e. < 1 month, glycaemia ≥ 2.5g/l).
研究者
相似试验
进行中（未招募）
1 期
RENAL SAFETY EVALUATION AFTER DOTAREM-ENHANCED MRI COMPARED WITH NON-ENHANCED MRI IN PATIENTS AT HIGH RISK OF DEVELOPING CONTRAST MEDIUM INDUCED NEPHROPATHY. - RESCUEEUCTR2007-000229-23-BEGUERBET134
已完成
4 期
Renal Safety Evaluation After Dotarem®-Enhanced MRIRenal InsufficiencyNCT00650845Guerbet135
进行中（未招募）
1 期
RENAL SAFETY EVALUATION AFTER DOTAREM-ENHANCED MRA COMPARED WITH NON-ENHANCED MRI IN PATIENTS AT HIGH RISK OF DEVELOPING CONTRAST MEDIUM INDUCED NEPHROPATHY.EUCTR2007-000229-23-FRGUERBET134
终止
3 期
Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)Renal Artery StenosisNCT00845702Guerbet33
终止
3 期
Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)Renal DiseaseNCT00980681Guerbet13